PT Kalbe Farma Tbk. (PTKFF)
OTCMKTS · Delayed Price · Currency is USD
0.0802
0.00 (0.00%)
At close: Oct 28, 2025
PT Kalbe Farma Tbk. Revenue
PT Kalbe Farma Tbk. had revenue of 8.91T IDR in the quarter ending September 30, 2025, with 12.62% growth. This brings the company's revenue in the last twelve months to 34.38T, up 7.00% year-over-year. In the year 2024, PT Kalbe Farma Tbk. had annual revenue of 32.63T with 7.16% growth.
Revenue (ttm)
34.38T IDR
Revenue Growth
+7.00%
P/S Ratio
1.68
Revenue / Employee
2.66B IDR
Employees
12,903
Market Cap
3.47B USD
Revenue Chart
* This company reports financials in IDR.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 32.63T | 2.18T | 7.16% |
| Dec 31, 2023 | 30.45T | 1.52T | 5.24% |
| Dec 31, 2022 | 28.93T | 2.67T | 10.18% |
| Dec 31, 2021 | 26.26T | 3.15T | 13.62% |
| Dec 31, 2020 | 23.11T | 479.18B | 2.12% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| American Oncology Network | 1.76B |
| Veradigm | 588.02M |
| Jushi Holdings | 256.36M |
| Glass House Brands | 221.55M |
| Elite Pharmaceuticals | 105.45M |
| Silence Therapeutics | 27.17M |
| Nuo Therapeutics | 1.95M |
| Northwest Biotherapeutics | 1.09M |